I-03 Hesham Al-Sallami Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients Wednesday 10:45-12:15 |
I-10 Charlotte Barker Population pharmacokinetics of benzylpenicillin in neonates in routine care Wednesday 10:45-12:15 |
I-20 Andrzej Bienczak Population Pharmacokinetic/Pharmacogenetic Analysis of Nevirapine in African Children Wednesday 10:45-12:15 |
I-25 Jennifer Bonner Building of a virtual paediatric cancer population for physiologically-based pharmacokinetic modelling and simulation in neonates, infants, and children Wednesday 10:45-12:15 |
I-33 Jantine Brussee Population modeling of cytochrome P450 mediated drug metabolism and oral absorption in preterm neonates receiving intravenous and oral midazolam in a cross-over study Wednesday 10:45-12:15 |
I-38 Elisa Calvier Extrapolation potential of semi-physiological covariate models to newborns: a simulation-based study Wednesday 10:45-12:15 |
I-66 Pieter De Cock Population cefazolin pharmacokinetics before, during and after cardiopulmonary bypass in children undergoing cardiac surgery Wednesday 10:45-12:15 |
I-71 Brenda de Winter Population pharmacokinetics of intravenous albuterol in children with status asthmaticus Wednesday 10:45-12:15 |
I-76 Paolo Denti Population Pharmacokinetics of Ofloxacin in South African children Wednesday 10:45-12:15 |
II-44 Pyry Välitalo Morphine efficacy in mechanically ventilated preterm neonates; an item response theory analysis Wednesday 15:15-16:40 |
II-50 Swantje Völler Comparison of current dose-reduction schemes for doxorubicin in young children using a recently developed population pharmacokinetic model Wednesday 15:15-16:40 |
II-56 Franziska Weber Pharmacometric approach to characterize key metabolites of acetaminophen in preterm and term neonates Wednesday 15:15-16:40 |
III-16 Aline Fuchs Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants Thursday 10:20-11:45 |
III-20 Eva Germovsek An Argument for Standardised Scaling: Comparison of Methods for Scaling Clearance in Children Thursday 10:20-11:45 |
III-42 Rollo Hoare Modelling CD4 T cell reconstitution in HIV-infected children starting antiretroviral therapy Thursday 10:20-11:45 |
III-48 Esther Janssen Population pharmacokinetic analysis of lamivudine in children aged 5 months – 18 years Thursday 10:20-11:45 |
III-59 Vincent Jullien Population pharmacokinetics of bumetanide in term newborn infants with seizures Thursday 10:20-11:45 |
IV-06 Jos Lommerse Raltegravir dosing in neonates (IMPAACT P1110) – Use of allometry and maturation in PK modeling to develop a daily dosing regimen for investigation during the first weeks of life. Thursday 15:20-16:40 |
IV-12 Adedeji Majekodunmi Impact of Hepatitis C coinfection on Immune reconstitution in HIV-infected children undergoing therapy Thursday 15:20-16:40 |
IV-24 Robin Michelet Bioequivalence of desmopressin in children: a population pharmacokinetic study Thursday 15:20-16:40 |
IV-38 Jaeseong Oh Population pharmacokinetic analysis of fluconazole in premature infants Thursday 15:20-16:40 |
IV-50 Sophie Peigné How modelling & simulation supported the drug development in children for a drug S Thursday 15:20-16:40 |
IV-52 Jonás Samuel Pérez-Blanco Age influence on clearance of phenobarbital in paediatric patients Thursday 15:20-16:40 |
IV-56 Caroline Petit Designing a paediatric study for an antimalarial drug including prior information from adults Thursday 15:20-16:40 |
IV-67 Su-jin Rhee A population pharmacokinetic analysis of once-daily intravenous busulfan in pediatric patients undergoing hematopoietic stem cell transplantation Thursday 15:20-16:40 |